RNS Number : 1248W
Smith & Nephew Plc
12 July 2024
 

 

SMITH & NEPHEW PLC

 

12 July 2024

 

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

 

On 11 July 2024, Smith & Nephew plc (the "Company") received notification of the following transactions as detailed below.

 

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc SPON ADR American Depositary Shares (ADS)

 

 

Identification code

ISIN: US83175M2052

Nature of the transaction

Purchase of American Depository Shares as participants of the Company's Employee Stock Purchase Plan

Date of Transaction

2024-07-5

Place of Transaction

New York Stock Exchange

 

Name

Director / PDMR

Price ($)

Volume

Aggregated information

Deepak Nath

(Chief Executive Officer)

 

Director

21.06

465.54938

N/A Single Transaction

Paul Connolly

(President, Global Operations)

PDMR

21.06

465.54938

N/A Single Transaction

Craig Gaffin

(President, Global Orthopaedics)

 

PDMR

21.06

465.54938

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

 

PDMR

21.06

108.48433

N/A Single Transaction

Scott Schaffner

(President, Sports Medicine)

PDMR

21.06

261.92498

N/A Single Transaction

 

 

Helen Barraclough

General Counsel and Company Secretary

Smith & Nephew plc

 

Tel:  +44 (0)1923 477100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFERDAILLIS